Knight Therapeutics Inc. GUD.TO
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -3.71% | 13.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.71% | 13.33% | |||
| Cost of Revenue | -6.80% | 17.90% | |||
| Gross Profit | -0.17% | 8.51% | |||
| SG&A Expenses | 5.40% | -1.26% | |||
| Depreciation & Amortization | -9.09% | 7.78% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.77% | 10.41% | |||
| Operating Income | -16.05% | 73.11% | |||
| Income Before Tax | -114.70% | 28.41% | |||
| Income Tax Expenses | 23.07% | -56.56% | |||
| Earnings from Continuing Operations | -125.30% | 51.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -125.30% | 51.16% | |||
| EBIT | -16.05% | 73.11% | |||
| EBITDA | -11.27% | 65.18% | |||
| EPS Basic | -125.33% | 52.58% | |||
| Normalized Basic EPS | -53.84% | 909.86% | |||
| EPS Diluted | -126.05% | 48.36% | |||
| Normalized Diluted EPS | -53.64% | 905.63% | |||
| Average Basic Shares Outstanding | -0.26% | -0.89% | |||
| Average Diluted Shares Outstanding | -0.74% | -0.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||